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1. Introduction 
Duchenne muscular dystrophy (DMD) is a genetic, X-chromosome recessive, severe and 
progressive muscle wasting disorder, affecting around 1 in 3500 newborn boys. The onset of 
the disease is in early childhood and, nowadays, most children are diagnosed before the age 
of 5. The first signs of muscular weakness become apparent around the age of 2 or 3 years. 
In most patients the age at which the child starts to walk is delayed (retarded motor 
development). The children have less endurance and difficulties with running and climbing 
stairs (Moser, 1984). Gower’s sign is a reflection of the weakness of the muscles of the lower 
extremities (knee and hip extensors): the child helps himself to get upright from sitting 
position by using his upper extremities: first by rising to stand on his arms and knees, and 
then “walking” his hands up his legs to stand upright (Gowers, 1895).  Muscle wasting is 
often symmetrical, however not all muscles are affected to the same extent. A prominent 
feature of the disease is enlargement of the calve muscle, caused by replacement of muscle 
fibres by connective and adipose tissue. Furthermore, the pelvic girdle, trunk and abdomen 
are severely affected and to a lesser extent the shoulder girdle and proximal muscles of the 
upper extremities. Progressive weakness and contractures of the leg muscles lead to 
wheelchair-dependency around the age of 10. Thereafter the muscle contractions increase 
rapidly leading to spinal deformities and scoliosis, often with an asymmetric distribution 
pattern. Involvement of the intercostal muscles and distortion of the thorax lead to 
respiratory failure and patients often require assisted ventilation in the mid to late teens. 
Thereafter dilated cardiomyopathy becomes apparent and most patients die before the age 
of 30. Another common feature is mental retardation (IQ less than 70) in around 20-30% of 
the patients (Emery, 2002). 
Becker Muscular Dystrophy (BMD) is a related, but much milder, form of muscular 
weakness, affecting around 1 in 20 000 men. The phenotype varies between individual 
patients, from very mild to moderately severe, but the course of the disease is more benign 
compared to DMD. On average, the age of onset is around 12 years; however some patients 
remain asymptomatic until much higher ages. The age of wheelchair-dependency also 
shows more variability, but in general is in their second or third decade of life. The most 
severely affected patients die between 40 and 50 years of age, whereas patients with a mild 
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phenotype have (nearly) normal life expectancies. Around 50% of patients also develops 
cardiomyopathy (Emery, 1993). 
The majority of female carriers shows no signs of disease. Only in 5 to 10% some degree of 
skeletal muscular weakness and enlarged calves are reported, but this is generally very mild 
and often does not affect daily activities. A small part of these carriers develops 
cardiomyopathy later in life; however most of the women with cardiac abnormalities on 
echocardiogram or ECG (left ventricular dilatation and decreased shortening fraction), are 
asymptomatic. There is no relation between the presence of skeletal muscle weakness and 
the development of cardiomyopathy (Grain et al., 2001). 
At present there is no cure for DMD. However, during the past decades pharmacological 
interventions and improved care (e.g. physiotherapy and assisted ventilation) have led to 
increased function and quality of life and prolonged life expectancy for currently diagnosed 
patients into their forties. The current standard of care also consists of corticosteroids 
(mainly predniso(lo)ne or deflazacourt). These are anti-inflammatory/immunosuppressive 
drugs that have shown to improve muscle function, prolong ambulation for around 3 years 
and to have a positive effect on cardiac function (Bushby et al., 2010). 
2. DMD gene and dystrophin protein 
2.1 Genetic defect in DMD 
DMD is caused by a genetic defect in the DMD gene. In approximately 33% of cases this is a 
de novo (new) mutation. The DMD gene is located on the short arm of the X-chromosome 
(at Xp21). It is the largest gene in the human genome consisting of 2 220 223 base pairs. The 
coding sequence spans around 0.5% (11 058 bases) of the gene, dispersed over 79 exons. 
Mutations in the gene causing a disruption of the open reading frame or introducing a 
premature stop codon lead to a complete absence of a functional dystrophin protein. 
Dystrophin consists of 3 685 amino acids and has a molecular weight of 427 kDa (Muntoni et 
al., 2003). The protein is located inside the muscle fibres and forms a bridge between the 
actin cytoskeleton and the extracellular matrix (ECM). Thereby it provides mechanical 
stability to the muscle fibres during each contraction. The protein consists of 4 domains: first 
an N-terminus, containing 2 actin-binding domains (ABD), both consisting of a CH1-and a 
CH2-domain, which are bound to contractile structures (F-actin) inside the muscle cells. This 
is followed by a central domain, so called central rod domain, consisting of 24 spectrin-like 
triple helical coiled repeat units, interrupted by 4 proline-rich hinge regions. A third actin-
binding domain is present between repeat 11 and 17 (Amann et al., 1998), while repeat 16-17 
contain a binding site for neuronal nitric oxide synthase (nNOS) (Lai et al., 2009). 
Subsequently the protein contains a cysteine-rich part and finally a C-terminal domain. The 
cysteine-rich domain binds to β-dystroglycan, which is part of a membrane bound 
dystrophin-associated glycoprotein complex (DGC) (fig. 1). B-dystroglycan is a 
transmembrane protein that is bound to the extracellular α-dystroglycan, which in turn is 
bound to laminin-2, a part of the extracellular matrix (ECM). The central rod domain can 
absorb mechanical force. Hereby the protein transmits energy produced by the actin-myosin 
contraction  machinery via the cell membranes to the connective tissue and tendons 
surrounding the muscles, to maintain the energy-balance and prevent overstressing of the 
muscle fibres (Ehmsen et al., 2002).  
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The dystrophin-associated glycoprotein complex (DGC) is composed of α- and β-dystroglycan, a 
sarcoglycan-sarcospan complex and the dystrophin containing cytoplasmic complex. Dystrophin 
(purple) forms the link between the actin cytoskeleton with its N-terminal domain and extracellular 
matrix component laminin-2 (lilac) via α- and β-dystroglycan (dark blue) with its C-terminal domain. B-
dystroglycan is also bound to the sarcoglycan-sarcospan complex (light blue/black) and to caveolin-3 
(orange), a scaffolding protein of skeletal muscle caveolae. Furthermore, the C-terminal domain of 
dystrophin is connected to α-dystrobrevin (green) and syntrophin (salmon pink), which recruits nNOS 
(yellow), a vasodilator, to the membrane. Α-dystrobrevin, in turn, is linked to syncoilin (brown), 
forming a bridge between the DGC and the desmin intermediate filament protein network (brown). 
Fig. 1. The dystrophin-associated glycoprotein complex 
In addition to its mechanical linker function, dystrophin is involved in the organisation of 
the DGC as well as many other proteins, the maintenance of the calcium homeostasis and 
control of the growth of the muscle cells (Hoffman et al., 1987). In the DGC, β-dystroglycan 
is connected to a complex of α-, β-, γ- and δ-sarcoglycans and sarcospan. This complex 
functions in maintaining membrane stability (Miller et al., 2007). B-dystroglycan is also 
bound to caveolin-3, a structural protein of skeletal muscle caveolae, small invaginations of 
the plasma membrane playing a role in, among others, signal transduction. Caveolins act as 
scaffolding proteins to compartmentalise and functionally regulate signalling molecules 
(Hezel et al., 2010). Furthermore, the C-terminal domain of dystrophin is connected to α-
dystrobrevin and syntrophin. nNOS is recruited to the membrane by binding to dystrophin 
and syntrophin. In contracting muscles, nNOS produces NO to induce vasodilatation in 
order to increase the local blood flow necessary for the increased mechanical load. The 
absence of nNOS in DMD causes abnormal vasoconstriction and ischemic stress, which 
contributes to the muscle degeneration (Brenman et al., 1995). Syntrophin is also connected 
to sodium channels, which are involved in regulating the Na+ distribution. In DMD, defects 
in cardiac conduction systems are thought to be caused by disturbances in Na+ distribution 
(Gee et al., 1998). A-dystrobrevin is linked to syncoilin too, thereby forming a bridge 
between the DGC and the desmin intermediate filament protein network at the 
neuromuscular junction (Newey et al., 2001).  
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Furthermore, in addition to the most common form of the dystrophin protein found in 
muscles, additional full-length and shorter isoforms of dystrophin exist. This is due to the 
presence of at least 7 different promoters and alternative splicing events. Three full-length 
variants exist (including the muscle isoform), which only differ in their first exon. In 
addition to the muscle promoter expressed in skeletal muscle and cardiomyocytes, a brain 
promoter drives expression in the cortical neurons and hippocampus of the brain and a 
Purkinje promoter in the cerebellar Purkinje cells. Four internal promoters lead to the 
production of shorter dystrophin proteins, lacking the actin-binding domains, expressed in 
specific tissues. In addition, alternative splicing facilitates the expression of many more 
dystrophins with a tissue-specific function (Muntoni et al., 2003).   
 
a.) In the normal situation pre-mRNA is spliced to produce mRNA, which in turn is translated into the 
dystrophin protein. This fully functional protein forms a bridge between the actin cytoskeleton and the 
extracellular matrix. b.) In DMD mutations lead to a disruption of the open reading frame and 
translation into protein stops prematurely. A truncated, non-functional dystrophin protein (which is 
degraded) is formed and the bridge function is lost. c.) In BMD mutations do not disrupt the open 
reading frame and translation into a shorter, but largely functional protein can occur. The bridge 
function is maintained. 
Fig. 2. The reading frame rule  
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2.2 Genetic defect in BMD 
In contrast to DMD, suffering from a complete absence dystrophin, in BMD a shorter, but 
partly functional, dystrophin protein is present. This discrepancy can be explained by the 
type of mutation that affects the DMD gene. In DMD mutations cause a disruption of the 
open reading frame or a premature stop codon, whereby the transcription of the gene stops 
prematurely and no functional protein is formed. In BMD the open reading frame stays 
intact (i.e. the size of the deletion in base pairs is divisible by 3), thereby translation can 
continue and a shorter protein is formed (fig. 2). This reading frame rule holds for over 90% 
of the cases (Aartsma-Rus et al., 2006b; Koenig et al., 1989). Only in-frame deletions that are 
very large (>36 exons) or deleting essential parts of the protein (the complete actin-binding 
domain or (part of) the cysteine-rich domain) lead to DMD. Furthermore, a small number of 
mutations that do disrupt the reading frame, lead to BMD instead of DMD (2%). This is 
probably due to correction of the reading frame at RNA level (Aartsma-Rus et al., 2006b). 
2.3 Animal models for DMD 
2.3.1 Mouse models for DMD 
The most widely used model for DMD is the mdx mouse model (C57Bl/10ScSn-DMDmdx/J). 
These mice have a single base substitution within exon 23, leading to a premature stop 
codon, so a truncated, non-functional dystrophin protein is formed (Sicinski et al., 1989). 
Despite the absence of dystrophin, the phenotype of the mdx mice is relatively mild 
compared to human DMD patients. However, compared to wild-type mice, their muscles 
are clearly dystrophic and functionally impaired (Chamberlain et al., 2007). Nevertheless, 
their life span is only slightly reduced and the muscular weakness is mild. This is probably 
due to compensatory mechanisms, like the upregulation of utrophin, a dystrophin 
homologue, which can partly take over its function. Mice that lack both dystrophin and 
utrophin (mdx/utrn-/-, double knock-out mice) show a very severe, progressive muscular 
dystrophy. Their muscles display several signs of damage and are rapidly replaced by 
fibrotic and adipose tissue. Furthermore, these mice are functionally impaired, have an 
arched spine and a life span of 20 weeks at maximum (Deconinck et al., 1997). Due to the 
very severe phenotype and short life span, mdx/utrn-/- mice are not practical as experimental 
model. An intermediate model is the mdx mouse with haploinsufficiency for utrophin 
(mdx/utrn+/-). Inflammation and fibrosis in both skeletal muscle and diaphragm are more 
severe than in the mdx mouse, but less than in the mdx/utrn-/- mouse. Their life span is 
significantly longer than that of mdx/utrn-/- mice (Zhou et al., 2008). 
Next to the naturally occurring mutation in the mdx mouse, several DMD mutations have 
been induced in mice. For example, treatment of mice with the chemical N-ethylnitrosourea 
(ENU), a powerful mutagen in mice, resulted in several new mdx-like mouse models 
(B6Ros.Cg-Dmdmdx–Cv/J). Mdx2Cv has a mutation in a splice site in exon 43 (causing 
alternative splicing, resulting in out-of-frame transcripts), mdx3Cv a mutation in intron 65 
(inducing a new splice site, resulting in out-of-frame transcripts), mdx4Cv a mutation in exon 
53 (premature stop codon) and mdx5Cv a mutation in exon 10 (frame-shift by introduction of 
a new splice site). All these mice have a phenotype comparable to the mdx mouse (Chapman 
et al., 1989). In addition, several mouse models have been generated that only affect 1 or a 
few of the different dystrophin isoforms. 
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2.3.2 Canine models for DMD 
The Golden retriever muscular dystrophy (GRMD) dog is a spontaneously occurring canine 
model for Duchenne muscular dystrophy. These dogs have a single base substitution in the 
3’ consensus splice site of intron 6, resulting in skipping of exon 7, thereby introducing a 
premature stop codon in exon 8. The course of the disease is more comparable to human 
patients than that of the mdx mouse. The dogs display rapid and fatal muscular dystrophy, 
characterised by muscle atrophy, myofibre degeneration, replacement by fibrotic and 
adipose tissue and cardiomyopathy (Sharp et al., 1992). Most affected animals die within a 
few years, mainly due to degeneration of the cardiac muscle (Howell et al., 1997). Although 
phenotypically the GRMD dog seems a better model for DMD, it shows a lot of 
interindividual variation in the severity of the pathology. Some animals die within days 
after birth, whereas others appear almost normal and live for years (Ambrosio et al., 2008). 
This makes the dogs less suitable for experimental use, due to standardisation problems. 
Because of the large size of the golden retriever, the GRMD dog has been bred with a much 
smaller beagle to generate the canine X-linked muscular dystrophy (CXMDj) model. These 
dogs have a milder phenotype compared to GRMD dogs and therefore have a longer life 
span (Shimatsu et al., 2003). 
In addition to the above mentioned large phenotypical variation, experiments with dogs are 
very costly. Dogs have a long breeding time and the availability is low (a heterozygous 
breeding program is needed, due to the severity of the phenotype). Furthermore, for 
therapeutic studies the size of the dogs requires large amounts of compound. 
3. Antisense oligonucleotide-mediated exon skipping 
3.1 Introduction antisense oligonucleotides 
Antisense oligonucleotides (AONs) are small synthetic pieces of DNA or RNA (15-30 bp), 
which are complementary to their target mRNA. Initially, DNA oligos were used for the 
specific knockdown of gene expression. These DNA oligos bind to the RNA to form DNA-
RNA hybrids which activate RNase H. This enzyme cleaves the double-stranded mRNA, 
thereby preventing the translation into protein, thus decreasing protein expression. DNA 
oligos are fast degraded by endonucleases, therefore oligos with a phosphorothioate instead 
of a phosphodiester backbone (PS DNA oligos) were developed, which are more 
endonuclease-resistant. These led to very efficient expression knockdown of for example 
genes (UL36 or IL2) involved in CMV retinitis (85-95%) (Baker & Monia, 1999). In addition 
to activation of RNase H, AONs can also down regulate gene expression by inducing 
translational arrest through steric hindrance of ribosomal activity, interference with mRNA 
maturation by inhibiting splicing or destabilisation of pre-mRNA in the nucleus (Chan et al., 
2006). Later, 2’O modified RNA oligos were developed, which have a higher affinity for 
mRNA and turned out not to induce RNase H-dependent cleavage (Sproat et al., 1989). The 
activation of RNase H is useful when down regulation of gene expression is required, but 
not when AONs are used for modulation of pre-mRNA splicing. 
3.1.1 Antisense-mediated exon skipping for DMD 
AON-mediated exon skipping for DMD is based on the reading frame rule (fig. 2), which 
underlies the phenotypic differences between DMD and BMD. Furthermore, in some DMD 
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patients rare, dystrophin-positive (so-called “revertant” fibres) were found, which are the 
result of spontaneous exon skipping or secondary mutations restoring the reading frame in 
these fibres and allowing dystrophin production. Therefore it was hypothesised that using 
AONs to induces skipping of specific exons could lead to the restoration of the reading 
frame and thereby production of slightly shorter dystrophin proteins, as found in BMD and 
revertant fibres (fig. 3) (van Ommen et al., 2008). This approach is mutation-specific and a 
large variety in mutations exists among DMD patients. Fortunately, 2 “hotspots” (a major 
around exon 43 to 53 and a minor spanning exons 2 to 20) exist, comprising a large 
proportion of the mutations (Aartsma-Rus et al., 2006b). In this Chapter we will describe the 
development of this therapeutic approach. We are aware that many excellent papers about 
exon skipping for DMD exist. Due to space constraints it was not feasible to cover them all. 
For a recent overview see Aartsma-Rus, RNA Biology 2010 (Aartsma-Rus, 2010).   
 
In DMD mutations in the DMD gene lead to a disruption of the open reading frame (in this example a 
deletion of exon 50), thereby preventing production of a functional dystrophin protein. Binding of an 
exon-specific AON (in this example against exon 51) hides the exon from the splicing machinery. The 
exon will be ‘skipped’ and not incorporated in the mRNA. Thereby the reading frame is restored and 
translation of a shorter, but still largely functional dystrophin protein can occur, which is similar to the 
proteins found in BMD. 
Fig. 3. Antisense oligonucleotide-mediated exon skipping 
3.2 Backbone chemistries 
To prevent activation of RNase H the 2’-O position of the ribose was modified (2’-O-methyl 
(2OME) or 2’-O-methoxyethyl (2OMOE)). Furthermore, various chemical modifications (fig. 
4) have been developed, which differ in sugar and backbone chemistry and have different 
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biophysical, biochemical and biological properties. For a more detailed review see Chan et 
al., Clin.Exp.Pharmacol.Physiol 2006 (Chan et al., 2006). The 2OMePS chemistry has an 
increased affinity for RNA and nuclear uptake. Disadvantages are that the phosphorothioate 
backbone is toxic to some extent and some sequences elicit an immune response. This is 
partly counteracted by the 2OMe modification. 
Peptide nucleic acids (PNA) contain a flexible, uncharged, achiral N-(2-aminoethyl)glycine 
backbone to which nucleobases are attached via methylenecarbonyl linkages in stead of the 
phosphodiester backbone of DNA oligos. PNAs have a high affinity for RNA, are not toxic 
even at high concentrations, are peptidase-and nuclease-resistant and have a high sequence-
specificity. A disadvantage is the insolubility of PNAs, due to their hydrophobic nature, 
which makes transfection difficult. This can be solved by the attachment of carrier groups, 
which easily bind to the peptide backbone, or addition of cationic lysine residues to the C-
terminus. Another disadvantage is the rapid clearance of PNAs in vivo. Their mechanism of 
action is mainly by steric hindrance (Larsen et al., 1999). 
Locked nucleic acid (LNA) DNA oligos contain a 2’-O, 4’-C-methylene bridge in the β-D-
ribofuranosyl configuration. They have a high hybridisation affinity towards target mRNA 
or DNA, thereby forming stable duplexes. This is an advantage, but also a disadvantage, 
since LNAs longer than 15 base pairs show self-annealing and are not very sequence-
specific, which increases the chance of unwanted side effects (Aartsma-Rus et al., 2004b). 
However, currently mainly LNA/2'-O-methyl oligonucleotide mixmers are used, which 
show much more sequence-specificity (Fabani & Gait, 2008). LNAs have a good nuclear 
uptake and are nuclease-resistant. 
Ethylene bridged nucleic acids (ENA) contain an ethylene bridge between the 2’-O and the 
4’-O-C of the ribose. They have similar properties to LNAs, but have a higher affinity to 
RNA, are very stable and more nuclease-resistant (Morita et al., 2002; Yagi et al., 2004). 
Phosphoroamidate morpholino oligomers (PMO) have a six-membered morpholino ring 
instead of the ribose sugar and the phosphodiester bond is replaced by a phosphoroamidate 
linkage. They do not activate RNase H, are very resistant to nucleases and are non-toxic. 
Furthermore, they are uncharged, which prevents undesired binding to proteins. However, 
this also results in limited nuclear uptake, where pre-mRNA splicing takes place. Their 
neutral charge also makes them hard to transfect in cell cultures, but in vivo PMOs can be 
taken up by tissues after local injection. This is probably due to the fact that the neutral 
nature does not form interactions with other cellular components. In general, PMOs are 
often a bit longer than 2OMePS AONs (25 nucleotides or more compared to around 20 
nucleotides for 2OMePSs). They primarily act by steric prevention of ribosomal assembly 
(Aartsma-Rus et al., 2004b; Chan et al., 2006; Heemskerk et al., 2009b). PMOs have been 
linked to arginine-rich cell-penetrating peptides (pPMOs) to increase uptake and efficiency. 
These conjugates indeed have higher efficacy, but there are toxicity concerns and the 
peptide might evoke an immune response (Moulton & Moulton, 2010), though this has not 
yet been observed. Conjugation of PMOs with a dendrimeric octaguanidine polymer (vivo-
morpholino) improves the delivery of the compound in vivo. Since this polymer is not a 
peptide, the risk of an immune response is small and has not been observed so far (Wu et al., 
2009), though the polymer is toxic at higher concentrations as well. 
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Phosphorothioate (PS) DNA, 2’-O-methyl phosphorothioate (2OMePS) RNA, 2’-O-methoxyethyl 
phosphorothioate (2OMOEPS) RNA, peptide nucleic acid (PNA), locked nucleic acid (LNA), ethylene 
bridged nucleic acid (ENA), phosphoroamidate morpholino (PMO) and dendrimeric octaguanidine 
conjugated phosphoroamidate morpholino (Vivo-PMO). 
Fig. 4. Chemical structure of different antisense oligonucleotides 
3.3 AON design and targets 
Target sites for exon skipping AONs are splice sites (SS), exonic splicing enhancer (ESE) 
sites or exon inclusion sequences (EIS). Splice sites are required for the correct identification 
of exons by the spliceosome, a catalytic complex that coordinates the splicing process and 
consists of 5 small nuclear ribonucleoproteins (snRNP) and hundreds of other splicing 
factors. The 5’ (donor) splice site (beginning of an intron), the branch point (just upstream of 
the acceptor splice site) and the 3’ (acceptor) splice site (end of an intron) contain consensus 
sequences that are bound by snRNPs and splicing factors to bring about the removal of 
introns and ligation of exons. Blockage of splice sites or the branch point prevents 
incorporation of the exon in the mRNA. Exon recognition is further facilitated by ESE sites, 
which are exonic sequence motives to which certain splicing factors (Ser-Arg-rich (SR) 
proteins) can bind. AONs targeting ESEs have been proposed to sterically hinder the 
binding of SR proteins (Aartsma-Rus et al., 2005; Aartsma-Rus et al., 2009b; Kole et al., 2004; 
Tanaka et al., 1994). 
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4. Antisense-mediated exon skipping in vitro 
4.1 Single exon skipping 
First proofs-of-principle for the feasibility of restoring the reading frame by exon skipping 
have been shown in vitro in cultured primary human myoblasts, derived from DMD 
patients and in mdx-cell cultures. 
In the early nineties, a DMD patient (named “DMD Kobe”) was identified carrying a 
deletion of 52 base pairs within exon 19, which led to the skipping of the whole exon. The 
authors hypothesised that this sequence might be important for splicing. An AON targeting 
part of this exon induced exon skipping in human control lymphoblastoid cells (Pramono et 
al., 1996; Takeshima et al., 1995). In cells derived from a patient with a deletion of exon 20, 
PS AONs (able to activate RNase H) against the aforementioned sequence, resulted in exon 
19 skipping and the restoration of dystrophin in ~20% of treated cells (Takeshima et al., 
2001). By that time, exon skipping with 2OMePS AONs (unable to activate RNase H), had 
also been explored. In 2 patients with an out-of-frame exon 45 deletion treatment with 
AONs resulted in exon 46 skipping, which should restore the open reading frame. Exon 
skipping levels were ~15%, which restored the synthesis of functional dystrophin in more 
than 75% of the cells (van Deutekom et al., 2001). Subsequently, the skipping of different 
exons has been reported for patient-derived cells with other deletions, point mutations and 
duplications. For an overview see Aartsma-Rus, RNA Biology 2010 (Aartsma-Rus, 2010). 
Restoration of dystrophin synthesis was detectable at the membrane and the (at least partial) 
functionality of these BMD-like proteins was suggested by the reformation of the 
dystrophin-glycoprotein complex, shown by increased membrane expression of DGC-
associated proteins. Another interesting finding were the higher exon skipping levels 
observed in these patient cell lines, than previously seen in control cell lines. This can be 
explained by nonsense-mediated decay (NMD) of the original out-of-frame transcripts, 
which are less stable than the newly formed in-frame transcripts (Aartsma-Rus et al., 2003). 
4.2 Double and multiple exon skipping 
In theory, skipping of a single exon would be beneficial for approximately 64% of the 
known mutations in DMD patients. However, there still is a large population which requires 
the skipping of 2 or more exons for reading frame restoration (Aartsma-Rus et al., 2009a). 
The theoretic applicability of exon skipping could be extended to 79% by double exon 
skipping and around 90% of patients by multiple exon skipping. Feasibility of double exon 
skipping was first shown in 2 different patient cell lines. One patient had a nonsense 
mutation in exon 43, for which dystrophin synthesis could be restored by skipping of exon 
43 and 44. The second, carrying an exon 46-50 deletion, was successfully treated with a 
combination of AONs against exon 45 and 51. Dystrophin synthesis was found in 70% of the 
myotubes, which is almost as high as after single exon skipping (75-80%) (Aartsma-Rus et 
al., 2004a). Subsequently, successful double exon skipping has been proved by other groups 
(reviewed in Aartsma-Rus, RNA Biology 2010 (Aartsma-Rus, 2010)). The dog model for DMD 
needs double skipping to bypass the mutation and cells derived from these dogs have been 
used to show double exon skipping in vitro (see below) (McClorey et al., 2006).   
A surprising finding in control myotubes was that combinational treatment with 45AON 
and 51AON caused the skipping of the entire stretch of exons from 45 through 51. This 
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would largely increase its therapeutic applicability for a number of different mutations. 
Indeed the same result could be induced in patient cells with an exon 48-50 deletion 
(Aartsma-Rus et al., 2004a). Skipping of other large stretches of exons (multiple exon 
skipping) however turned out to be technically challenging and has had limited success so 
far (Aartsma-Rus et al., 2006a). The use of several ratios of 45AON and 55AON in both 
control as patient cell lines resulted in undetectable to very low exon 45-55 skipping 
frequencies (van Vliet L. et al., 2008).  
Exon skipping is in theory useful for the majority of patients. Exceptions are mutations that 
involve regions in the gene that are essential for the function of the dystrophin protein: all 
actin-binding N-terminal parts, the cysteine-rich C-terminal part (binding to the DGC-
complex), the promoter region or the first exon. Furthermore it is not applicable to 
translocations. Fortunately these kind of mutations make up only a small part (~8%) of all 
known mutations (Aartsma-Rus et al., 2009a). The largest part of mutations is made up by 
deletions and small mutations. A minor part consists of exon duplications (double or 
multiple). In the case of single duplications, skipping of one of these exons would in theory 
generate wild-type dystrophin transcripts. However, this turned out to be challenging. In 
cells with an exon 45 duplication this was indeed possible, but in other cases the skipping 
was so efficient that both exons were skipped, leading to an out-of-frame transcript 
(Aartsma-Rus et al., 2007). Skipping of an additional exon could restore the reading frame 
again. For example for an exon 18 duplication, successful skipping of exon 17 and both exon 
18s resulted in restoration of the reading frame (Forrest et al., 2010). Successful skipping of 
multiple exon duplications has not yet been achieved (Aartsma-Rus et al., 2007). In total 6% 
of patients could benefit from single or multiple skipping of exon duplications. 
5. Antisense-mediated exon skipping in vivo in animal models 
5.1 AONs in mouse models for DMD 
5.1.1 AONs in the mdx mouse model 
After the promising in vitro results, AONs have been tested in vivo in animal models. As 
mentioned before, the mdx mouse is most widely used. The target site for exon 23 was first 
optimised in mdx myotube cell cultures. This resulted in a 5’ splice site targeting AON with 
a 2’-O-methoxyethyl phosphorothioate (2OMePS) backbone, which was tested locally in the 
mdx mouse. A single intramuscular injection of this compound in the tibialis anterior of both 
young (2 or 4 weeks old) and aged (6 months old) mice resulted in marked dystrophin 
expression 2 weeks after injection, which persisted up to 3 months after injection. The 
functionality of the dystrophin protein was suggested by the re-expression of dystroglycans, 
sarcoglycans and nNOS at the membrane. It also resulted in partial restoration of 
physiological function, maximum isometric titanic force, of the treated muscles. Importantly 
no auto-immune response against the newly formed dystrophin protein was observed (Lu et 
al., 2003). Of course, since DMD affects body-wide musculature, including heart and 
diaphragm, injection of every muscle separately is not feasible and systemic treatment is 
required. Three intravenous injections at weekly intervals resulted in dystrophin expression, 
highest in gastrocnemius, intercostal muscles and the diaphragm, without signs of toxicity 
or damage to other organs. However dystrophin could not be detected in the cardiac muscle 
(Lu et al., 2005). To optimise delivery and efficiency, different administration routes have 
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been compared. Intravenous injection resulted rapidly in high plasma levels, which were 
quickly cleared. Peak plasma levels were twofold lower after subcutaneous and 
intraperitoneal injection, but clearance was much slower. Furthermore, intravenous injection 
resulted in very high AON levels in the kidney and liver, which might induce toxicity after 
long term treatment. Skipping levels were highest after intravenous injection and slightly 
lower for both subcutaneous and intraperitoneal injection. Dystrophin expression followed 
a similar pattern. Importantly, all 3 routes resulted in exon skipping and dystrophin 
expression in the heart, albeit at low levels. Due to the better pharmacokinetic profile of 
subcutaneous versus intravenous injection and slightly higher exon skipping compared to 
intraperitoneal administration, subcutaneous injection seemed to be the delivery method of 
choice. After subcutaneous treatment also a decrease in serum creatine kinase (CK) levels 
was observed. Creatine kinase is an enzyme that leaks out of the muscles into the blood 
stream when muscles are damaged, so a decrease indicates an improvement of muscle 
integrity (Heemskerk et al., 2010).  
Morpholino (PMO) AONs have been shown to be effective in vivo as well. Intramuscular 
injection in the tibialis anterior elicited a dose-dependent increase in dystrophin expression 
in the majority of muscle fibres and dystrophin protein levels up to 60% of levels found in 
healthy muscle. Efficiency was comparable in both young (3 weeks old) and aged (6 months 
old) mdx mice. Repeated systemic (intravenous) injections induced exon skipping and 
expression of dystrophin protein body-wide, albeit with large variations between individual 
muscles. Highest levels were found in the quadriceps, abdominal and intercostal muscles. 
Lower levels were found in the tibialis anterior and diaphragm. CK levels were decreased 
and muscle function was improved as well. As with 2OMePS AONs, targeting of the cardiac 
muscle appeared difficult, since exon skipping and dystrophin expression were 
undetectable (Alter et al., 2006). Wu et al. showed that dystrophin restoration could be 
achieved (up to 30% of healthy levels) by systemic PMO treatment, although extremely high 
doses (up to 3 g/kg bodyweight) were required (Wu et al., 2010). Furthermore, a dosing 
regime of multiple low doses seems to be preferable above a few high doses to reduce the 
risk of toxicity and increase the efficiency, since both AONs and dystrophin protein show an  
accumulation over time (Malerba et al., 2009). 
In the mdx mouse model PMOs appeared more effective and at lower doses compared to 
2OMePS AONs. A direct comparison revealed that this was indeed the case for mouse exon 
23 in the mdx mouse. Intramuscular injection of both AONs in the gastrocnemius, resulted in 
much higher skipping levels for PMOs than for 2OMePS AONs at the same molar amount. 
Systemic (intravenous) comparison in the mdx mouse showed, as had been noticed before, 
that most of the 2OMePS AONs are taken up by the liver and kidney. However the PMOs 
were almost exclusively taken up by the kidney. A possible explanation is that 2OMePS 
AONs bind to serum proteins, which prevents renal clearance (Geary et al., 2001), whereas 
PMOs do not, which explains their high renal clearance (Oberbauer et al., 1995). 2OMePS 
AON uptake was higher for all skeletal muscles, diaphragm and heart. In contrast to the 
biodistribution, exon skipping efficiency was much higher for the PMO AONs in skeletal 
muscle and diaphragm (approximately 40% versus 10%). Skipping levels in the heart were 
much lower and almost comparable between both compounds (2.5% for the PMOs versus 
1.5% for the 2OMePS AONs). Protein levels followed the same pattern (Heemskerk et al., 
2009b).  
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A PMO conjugated to a cell-penetrating peptide (pPMO) showed to be more effective than 
the naked PMO AON. Systemic (intravenous) treatment of mdx mice was very potent in 
both skeletal muscle, diaphragm and, importantly, heart. pPMOs lead to a decrease in CK 
levels (Jearawiriyapaisarn et al., 2008). Another study confirmed that the long term systemic 
treatment with pPMOs was effective in restoring dystrophin expression in skeletal muscle, 
improving muscle function and preventing heart failure (Wu et al., 2008). These pPMOs 
were also able to rescue the severe mdx/utrn-/-- mouse model by systemic (intraperitoneal) 
treatment. Considerable improvement of muscle function was observed, combined with 
dystrophin expression in almost all muscles, except for the heart (Goyenvalle et al., 2010). 
Peptides might elicit an immune response, but no signs of such a response or toxicity were 
found in the mouse models so far. Unfortunately, when a pPMO compound was tested in 
primates, there were toxicity concerns. In cynomolgus monkeys pPMO doses equivalent to 
the ones used in mice, were not toxic, but also had little exon skipping effect. Higher doses 
were effective, but also caused tubular degeneration in the kidneys, a sign of renal toxicity 
(Moulton & Moulton, 2010). Yin et al. generated a chimeric fusion peptide consisting of a 
muscle-targeting heptapeptide (MSP) fused to an arginine-rich cell-penetrating peptide (B-
peptide), which they conjugated to a PMO oligomer (B-MSP-PMO). These B-MSP-PMOs 
were already efficient at very low doses in restoring high levels of dystrophin expression 
body-wide (Yin et al., 2009). Novel cell-penetrating peptides have been discovered by 
inducing modifications to a Drosophila melanogaster-derived R6-Penetratin peptide. These 
peptides are called PNA or PMO internalisation peptides (Pips). A conjugate of Pip2b and a 
PNA AON (Pip2b-PNA) resulted in approximately threefold higher dystrophin-positive 
fibres compared to the naked AON after local injection in the tibialis anterior of mdx mice 
(Ivanova et al., 2008). More and improved Pips have been developed. Pip5e fused with a 
PMO (Pip5e-PMO) showed high exon skipping efficiency after a single intravenous injection 
in the mdx mouse. Most importantly it also efficiently targeted the heart, leading to 
dystrophin levels of more than 50% of wild-type levels (Yin et al., 2011). 
Another modification of the PMO is conjugation to a dendrimeric octaguanidine polymer 
(vivo-morpholino). This modification also significantly improved the delivery and 
dystrophin production in mdx mice after intravenous injection. Repeated treatment resulted 
in dystrophin expression in almost 100% of the skeletal muscle fibres and levels of protein 
up to 50% of wild-type levels. Importantly, levels of ~10% of those found in healthy hearts 
were found in the cardiac muscle. In these mice no signs of an immune response or toxicity 
were observed (Wu et al., 2009). 
5.1.2 AONs in the other mouse models 
Both 2OMePS and PMO AONs have also been tested in the mdx4Cv mouse. These mice 
require skipping of both exon 52 and 53 to remove the mutation and maintain the reading 
frame. Immortalised myoblast cell cultures from these mice were used to design the most 
effective AONs against exon 52 and 53, which were then tested in vivo in the mdx4Cv mice. 
2OMePS AONs induced exon skipping in these cell cultures, but no dystrophin protein was 
observed. Intramuscular injection of the cocktail of AONs in the tibialis anterior resulted in 
sporadic exon skipping in this muscle, but no detection of dystrophin protein. A 
combination of PMO AONs against both exons resulted both in vitro and in vivo (after 
injection in the tibialis anterior) in exon skipping and restoration of dystrophin expression 
(Mitrpant et al., 2009). 
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AONs are sequence-, and therefore species-, specific. So, to be able to test human-specific 
AONs, a mouse containing the full-length human DMD gene was generated (hDMD). These 
mice have a fully functional hDMD transgene integrated on mouse chromosome 5. The 
functionality of the transgene was proven by rescuing the severe dystrophic phenotype of 
the mdx/utrn-/- mouse after crossing of both models ('t Hoen et al., 2008).  Intramuscular 
injection (gastrocnemius) of 2OMePS AONs against exon 44, 46 or 49, induced specific 
skipping of the targeted human exons. It also highlighted the sequence-specificity of the 
AONs, since in the corresponding mouse sequences, with only 2 or 3 mismatches, no 
detectable skipping was observed (Bremmer-Bout et al., 2004). As described before, PMOs 
were more efficient in the mdx mouse than 2OMePS AONs.  However in the hDMD mouse, 
AONs targeting human exon 44, 45, 46 or 51 were comparably effective or only marginally 
different between both chemistries. This indicated that the differences between PMO and 
2OMePS AONs are probably more due to sequence differences than to chemistry 
differences. Furthermore, it also suggested important differences in sequence-specificity. 
2OMePS AONs with 2 mismatches had a greatly reduced efficiency, whereas PMO AONs 
remained equally effective. This can increase the risk of off-target side effects (Heemskerk et 
al., 2009b). 
Studies in these hDMD mice revealed that the uptake of AON by the healthy hDMD muscle 
fibres is much lower than by dystrophic mdx fibres. This can probably be explained by the 
dystrophic nature of the mdx fibres: the lack of dystrophin results in damage to the muscle 
fibres, leading to leakage of the muscle enzyme creatine kinase into the bloodstream. It has 
been proposed that the AONs migrate into the muscle fibres through these same holes 
(Hoffman, 2007). In this way the disease is facilitating delivery of the potential therapeutic 
compound. Indeed AON uptake and skipping in the hDMD mouse is more difficult. The 
exon skipping levels observed after intramuscular injection with either 2OMePS or PMO 
AONs were lower than previously observed in the mdx mouse and in cell cultures 
(Heemskerk et al., 2009a).  A pilot experiment with systemic (intravenous) injection of 
2OMePS AONs targeting exon 51 in the hDMD mouse resulted in very low or undetectable 
exon skipping in the muscles (Heemskerk et al., 2010). Recently, vivo-morpholinos against 
exon 50 were shown to be able to achieve high levels of exon skipping after systemic 
(intravenous) injection in the healthy skeletal muscles of the hDMD mouse and even low 
levels in the cardiac muscle. There were no large signs of toxicity or adverse effects, only a 
small increase in serum CK levels, which could reflect a bit of membrane integrity 
disturbance (Wu et al., 2011). The influence of the nature of the muscle fibres on AON 
delivery efficiency might also explain why targeting of the heart is so difficult. The heart 
muscle is structurally and pathologically different from skeletal muscle, since it is made up 
of individual cardiomyocytes, which do not become ‘leaky’. 
5.2 AONs in the canine models 
First AON experiments with the canine model have been performed in vitro in myoblast cell 
cultures of the GRMD dog. The nature of the mutation requires the skipping of 2 exons 
(exon 6 and exon 8) to restore the reading frame, thereby making it more challenging. In 
vitro, 2OMePS AONs induced higher exon skipping levels than the PMOs, but only for a 
short term and without induction of detectable dystrophin protein. PMOs could restore a 
low level of dystrophin production, but only at very high concentrations. pPMOs could 
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induce slightly higher exon skipping levels and restored dystrophin expression (McClorey 
et al., 2006). Further testing of these AON cocktails in vivo by intramuscular injections, 
revealed that the AONs targeting exon 8 were effective, but the AONs targeting exon 6, 
which showed effectiveness in vitro, were not (Partridge, 2010). Another small experiment 
(in a 6 months old and a 5 years old dog) with cocktails of 2OMePS AONs or PMOs, 
resulted in high skipping levels of the desired exons and restoration of dystrophin protein to 
near normal levels after a single injection in the tibialis anterior with the highest test dose. 
The structure of the dystrophin-positive cells was reported to be improved. Furthermore, 
both backbone chemistries showed comparable results and results were better in the 
younger dog than in the older dog (Scheuerbrandt, 2009). 
Systemic (intravenous) treatment of CXMDj dogs with a cocktail of 3 PMO AONs targeting 
exon 6 (2 PMOs) and exon 8 (1 PMO), generated body-wide production of functional 
dystrophin. In the heart there was only modest production of dystrophin, as observed in 
mice. Furthermore, an interindividual variation between dogs and intra-individual variation 
between different muscles of the same dog was seen. Functional improvement could be 
shown too and no signs of toxicity were observed (Yokota et al., 2009). 
6. Clinical trials with antisense-mediated exon skipping 
6.1 Local treatment with AONs 
After the promising preclinical results in vitro and in vivo, the first clinical trials were 
initiated. These trials used local (intramuscular) injections to obtain proof-of-principle in 
humans and examine possible adverse effects. Normally, the first human trials are done in 
healthy volunteers (phase I). However, this is not possible in this case, since exon skipping 
in healthy persons would result in disruption of the reading frame. Therefore this phase was 
skipped and AONs were tested immediately in DMD patients (phase I). These first trials 
focused on skipping of exon 51 for both 2OMePS (in 2006) and PMO AONs (in 2008), since 
this would be applicable to the relatively largest group of known mutations (13%) (Aartsma-
Rus et al., 2009a). 
A single injection in the tibialis anterior with 0.8 mg of a 2OMePS AON (called PRO051) in 4 
patients resulted in specific exon 51 skipping without adverse effects. It restored dystrophin 
expression at the sarcolemma in 64-97% of the myofibres and restored protein levels till 17-
35% of control levels. However, it also clearly indicated the importance of muscle quality 
since the target of AONs, the dystrophin transcript, is only expressed in muscle fibres and 
not in adipose and fibrotic tissue, which replaces the muscle tissue when the disease 
progresses. The patient with the lowest dystrophin levels had the most advanced disease 
state and relatively little muscle tissue left (van Deutekom et al., 2007). 
For PMO AONs a placebo-controlled, single-blinded study was performed. Seven patients 
received an injection with a PMO AON (called AVI-4658) into their extensor digitorum 
brevis (EDB) and saline into the contralateral muscle. In 2 patients receiving the lowest dose 
(0.09 mg) this resulted in low levels of exon 51 skipping, but no observed increase in 
dystrophin expression. However, a clear dystrophin restoration was observed in the higher 
dose (0.9 mg) group. As for the PRO051 study no adverse events, like an inflammatory 
response, were observed. Immunofluorescent staining for dystrophin indicated 11-21% 
higher intensity levels in the AON-treated muscle compared to the contralateral saline-
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treated muscle, and levels of 22-32% of control dystrophin levels (Kinali et al., 2009). Since 
both studies studied different muscles and used different techniques for quantifying 
immunocytochemistry the results are not directly comparable (Aartsma-Rus & van Ommen, 
2009). However both studies showed unequivocal effectiveness of the used compound in the 
absence of side effects. 
6.2 Systemic treatment with AONs 
The next step towards clinical application of exon skipping are systemic clinical trials. The 
first pilot experiment has been conducted in Japan. Takeshima et al. treated 1 DMD patient 
intravenously with a weekly dose of 0.5 mg/kg bodyweight of a PS AON against exon 19 
for 4 weeks. Only very low levels of exon skipping and dystrophin protein were observed in 
a muscle biopsy (Takeshima et al., 2006). This is not surprising, as the dose used was very 
low and the PS backbone chemistry is not ideal for exon skipping purposes (see above). 
Furthermore, this was only 1 single patient, so no real, reliable conclusions can be drawn 
from this experiment. 
More extensive, open-label, dose-escalation, phase I/IIa studies have recently been 
completed for both 2OMePS and PMO AONs. The first was a study with abdominal 
subcutaneous injections of PRO051 (2OMePS AON, now called GSK2402968)) in 12 patients 
testing 5 weekly doses (0.5, 2, 4 and 6 mg/kg bodyweight) in groups of 3 patients. Doses of 2 
mg/kg bodyweight or higher resulted in specific exon 51 skipping. In 10 out of 12 patients 
dystrophin expression in a tibialis anterior biopsy could be observed in 60-100% of the 
muscle fibres at levels up to 15.6% of healthy levels in a dose-dependent manner. After 
analysis of this first phase (6 to 15 months later), all patients entered an open-label extension 
study in which they received weekly injections of the highest dose. After 12 weeks, this 
resulted in functional improvement as measured by the 6-minute walk test. Since a placebo 
group is lacking, interpretation of this improvement must be done with caution. 
Nevertheless, the overall results are encouraging and only mild adverse events, like 
irritation at the injection side and mild proteinuria, were observed (Goemans et al., 2011). 
AVI-4658 (PMO AON, also called eteplirsen) was tested by 12 weekly intravenous infusions 
of different doses (0.5, 1, 2, 4, 10 and 20 mg/kg bodyweight) in a total of 19 patients, without 
serious adverse events. In a biceps biopsy, exon 51 skipping and restoration of protein 
expression was observed starting at a dose of 2 mg/kg bodyweight, albeit variable between 
individual patients. The responding patients showed dystrophin levels of 8-16% of healthy 
controls by immunofluorescent staining. Notably, there were 3 patients who responded very 
well, with up to 55% of dystrophin-positive fibres by immunofluorescent staining and 
dystrophin levels up to 18% by western blot. In 4 other patients some improvement was 
observed. Furthermore, the functionality of the newly formed proteins was confirmed by 
the restoration of DGC-associated proteins at the sarcolemma. In addition, a reduction of 
inflammatory infiltrates was observed in the highest dose group, which probably indicates a 
reduction in necrosis and an increased resistance to mechanical load (Cirak et al., 2011). Not 
all patients responded equally well, which may be explained by the short serum half-life of 
PMOs. Since PMOs do not bind to plasma proteins (see above), they are rapidly filtered out 
by the kidney (accounting for 40-60% of total plasma clearance). Thus, the amount available 
for uptake by other tissues (e.g. muscles) is low. Therefore further optimisation (e.g. higher 
doses) is needed. 
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The next steps are larger randomised, placebo-controlled studies and targeting of other 
exons. For GSK2402968 a phase III study was initiated in January 2011. 180 ambulant 
patients will receive 6 mg/kg bodyweight AON once weekly for 1 year or placebo 
(http://clinicaltrials.gov/ct2/show/NCT01254019?term=GSK2402968&rank=1). This study 
will tell us whether long-term treatment is safe and leads to functional improvement or 
slowing down of disease progression (compared to placebo-treated patients). In parallel,  
a study in non-ambulant patients with different AON doses, primarily to  
determine the pharmacokinetical profile in older patients, and a study in  
ambulant patients where different treatment regimes are compared, are conducted 
(http://clinicaltrials.gov/ct2/show/NCT01128855?term=GSK2402968&rank=3 and 
http://clinicaltrials.gov/ct2/show/NCT01153932?term=GSK2402968&rank=2). In addition 
a clinical trial for AVI-4658 (eteplirsen) with higher doses (30 mg/kg and 50 mg/kg 
bodyweight) for 24 weeks has been initiated to assess its efficacy and safety 
(http://clinicaltrials.gov/ct2/show/NCT01396239?term=eteplirsen&rank=1). These trials 
focus on skipping of exon 51, applicable to the relative largest group of patients. Skipping of 
exon 44 would be useful for another large group of patients (6.2%) (Aartsma-Rus et al., 
2006b). A phase I/IIa study with PRO044 (2OMePS AON against exon 44)  
with the same set-up as the phase I/IIa study for PRO051 is currently ongoing 
(http://clinicaltrials.gov/ct2/show/NCT01037309?term=PRO044&rank1). Furthermore, 
preclinical studies with other 2OMePS AONs (against exon 45, 52, 53 and 55) are performed 
by Prosensa Therapeutics. In addition to this, preclinical tests with AVI-5038 (pPMO AON 
against exon 50) are ongoing, although toxicity issues with this pPMO have been reported 
(http://investorrelations.avibio.com/phoenix.zhtml?c=64231%20&p=irol-
newsArticle&ID=1406001&highlight=). 
7. Improvement of AON delivery and efficiency 
The efficacy of AONs depends partly on the amount of AON that reaches its target, i.e. the 
muscle fibre nuclei. Several strategies to improve muscle-specific uptake are under 
investigation, like muscle-homing peptides and cell-penetrating peptides (see above). Due to 
AON clearance and turnover, the effect of AONs is only temporarily, thus repeated, life-long, 
injections are required, should this approach prove to be efficacious. The first clinical trials 
showed that the average serum half-life was 29 days for 2OMePS AONs and around 1.5 hours 
for PMOs. A way to allow a more prolonged effect is the use of viral vectors stably expressing 
modified small nuclear ribonucleoprotein (snRNP) genes, in which the normal antisense 
sequence is replaced by an antisense sequence of choice. snRNPs are small protein-RNA 
hybrids that are amongst others involved in pre-mRNA splicing and histone processing. The 
U1 and U7 snRNPs have been used most in splicing modulation experiments (Brun et al., 
2003). Exon 51 targeting U1 snRNPs induced effective skipping of exon 51 and rescue of 
dystrophin synthesis in a patient-derived cell line (De Angelis et al., 2002). Adeno-associated 
viruses (AAVs) are very efficient at transferring genes into skeletal muscles. Injection of AAV 
vectors expressing U7 or U1 snRNPs targeting mouse exon 23 resulted in sustained production 
of functional dystrophin in the mdx mouse after intramuscular injection and body-wide 
dystrophin expression and reduced muscle wasting after systemic treatment (Denti et al., 2008; 
Goyenvalle et al., 2004). However serious problems with the use of AAV vectors are the 
possibility of an immune response against the viral capsid and the difficulty to produce them 
on a large scale under good manufacturing practice (GMP), necessary for implementation in 
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the clinic. Another problem is the translation from mice to larger animals or humans. In mice it 
is feasible to treat a whole muscle, but transfection of whole muscles body-wide is more 
challenging in larger animals and humans. 
8. Conclusion 
In summary, Duchenne muscular dystrophy is caused by genetic defects in the gene 
encoding the dystrophin protein. These mutations cause a premature stop codon or disrupt 
the reading frame, leading to a non-functional protein. In most cases this can be overcome 
by specific skipping of the mutated exon with AONs, to produce a slightly shorter, but 
largely functional dystrophin protein, as found in the related, but much milder Becker 
muscular dystrophy. Over the past years major steps have been made in development of 
this therapy. Proof-of-principle has first been shown in vitro in cultured muscle cell lines and 
in vivo in several animal models (e.g. mdx mice and GRMD dogs). Recently the first clinical 
trials with AONs of 2 different chemistries, targeting exon 51, applicable to the largest group 
of patients, have been completed with positive results. Larger trials are ongoing or planned 
for the near future. Although the results obtained in the past few years are very 
encouraging, precaution is needed and several problems still exist. First of all, this is not a 
cure, but a potential treatment that will hopefully lead to an improvement of the phenotype. 
Secondly, the approach is mutation-specific, i.e. requiring different AONs for different 
mutations. Luckily most mutations cluster in 2 hotspots (see above). However, development 
and application in the clinic of the therapy for rare mutations will be difficult, since at the 
moment each AON is considered as a new drug, therefore has to go through all (pre)clinical 
steps before it can be registered. For these rare mutations simply not enough patients are 
available for these studies. At the moment efforts to discuss this with the regulatory 
authorities are coordinated by the TREAT-NMD Network of Excellence. For example, it may 
be possible to reduce the toxicity trials for an AON with similar backbone chemistry, if 1 or 
2 of this kind have been proven to be safe (Muntoni & Wood, 2011). Thirdly, the approach 
will not be useful for mutations affecting the essential parts (actin-or dystroglycan-binding 
domains) of the protein. Fortunately these make up only a small percentage of all known 
mutations. Furthermore, restoration of the reading frame is more challenging when double 
and especially multiple exon skipping is required. Finally, the preclinical studies and first 
clinical trials have shown that muscle quality is very important for the therapeutic success, 
since dystrophin transcripts are only produced in muscle cells and not in the fibrotic and 
adipose tissue that replaces the muscle cells when the disease progresses. Therefore early 
start of treatment will probably be required. 
In conclusion, AONs are currently a promising therapeutic approach for DMD and major 
steps towards clinical implementation have been made over the past years, but further 
improvements are necessary for increasing therapeutic effectiveness and more research for 
broader clinical application of the technique. 
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